Endomyocardial Botulinum Toxin Injection in Patients With Persistent Atrial Fibrillation
| Status: | Recruiting |
|---|---|
| Conditions: | Atrial Fibrillation |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - 70 |
| Updated: | 4/21/2016 |
| Start Date: | June 2013 |
| End Date: | January 2016 |
| Contact: | Evgeny Pokushalov, MD, PhD |
| Email: | e.pokushalov@gmail.com |
| Phone: | +79139254858 |
The investigators have conducted a prospective, double-blind, randomized study to assess the
comparative safety and efficacy of two different ablation strategies, PVI plus linear
lesions (LL) plus botulinum toxin injection versus PVI plus linear lesions (LL), in patients
with persistent or longstanding persistent AF. Results were assessed with the use of an
implanted monitoring device (IMD).
comparative safety and efficacy of two different ablation strategies, PVI plus linear
lesions (LL) plus botulinum toxin injection versus PVI plus linear lesions (LL), in patients
with persistent or longstanding persistent AF. Results were assessed with the use of an
implanted monitoring device (IMD).
Inclusion Criteria:
- Persistent and longstanding persistent AF
Exclusion Criteria:
- congestive heart failure
- LV ejection fraction < 35%
- left atrial diameter > 60 mm
We found this trial at
2
sites
Novosibirsk, 63005
Principal Investigator: Evgeny Pokushalov, MD, PhD
Phone: +79139254858
Click here to add this to my saved trials
University of Rochester The University of Rochester is one of the country's top-tier research universities....
Click here to add this to my saved trials